ClinicalTrials.gg
CompletedNCT03254966Updated Sep 30, 2021

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

A Phase 2 interventional study of SHR0302 and Placebo in Rheumatoid Arthritis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-09-30.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
2nd of 11
194 · median 30
Started
2017
the only one that year
Phase 2
2 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 2 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects who are 18 - 70 (inclusive) years of age on the day of signing
  • have a diagnosis of RA meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III
  • have ≥6 swollen joints (from a 66-joint count) and ≥8 tender joints (from a 68-joint count) at Screening and at Baseline, Screening serum c-reactive protein (CRP)or hsCRP > 1.2 x upper limit of laboratory normal range (),or erythrocyte sedimentation rate (ESR) > 28 mm/h
  • have not used any disease modifying anti-rheumatic drug (DMARD) or have an inadequate response to one or more kinds of conditional DMARDs (methotrexate, leflunomide, Chloroquine, hydroxychloroquine, sulfasalazine, minocycline, penicillamine, auranofin or injection gold preparation, and iguratimod) due to lack of efficacy or toxicity, and have agreed to be washed out from these conditional DMARDs for a period of at least 7 t1/2s prior to randomization, with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to randomization
  • (BMI = weight/height squared (kg/m2)) within the range of 18 to 35,

Exclusion criteria

Exclusion Criteria:

  • current or previous RA treatment with a jak inhibitor
  • current or previous RA treatment with a biologic DMARD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    SHR0302 dose level 1

    Drug: SHR0302

  • Experimental
    SHR0302 dose level 2

    Drug: SHR0302

  • Experimental
    SHR0302 dose level 3

    Drug: SHR0302

  • Experimental
    SHR0302 dose level 4

    Drug: SHR0302

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieving an American College of Rheumatology (ACR)20 response at Week 12

    Time frame: Baseline - Week 12

Secondary outcomes

  1. Percentage of subjects achieving an American College of Rheumatology (ACR)20 response at Week 24

    Time frame: Baseline - Week 24

  2. Percentage of subjects achieving an American College of Rheumatology (ACR)50 response at Week 12

    Time frame: Baseline - Week 12

  3. Percentage of subjects achieving an American College of Rheumatology (ACR)50 response at Week 24

    Time frame: Baseline - Week 24

  4. Percentage of subjects achieving an American College of Rheumatology (ACR)70 response at Week 12

    Time frame: Baseline - Week 12

  5. Percentage of subjects achieving an American College of Rheumatology (ACR)70 response at Week 24

    Time frame: Baseline - Week 24

  6. Percentage of subjects achieving DAS28-3(CRP)<2.6 at Week 12

    Time frame: Baseline - Week 12

  7. Percentage of subjects achieving DAS28-3(CRP)<2.6 at Week 24

    Time frame: Baseline - Week 24

  8. Change from baseline in the Health Assessment Questionaire (HAQ-DI) at week 12

    Time frame: Baseline - Week 12

  9. Change from baseline in the Health Assessment Questionaire (HAQ-DI) at week 24

    Time frame: Baseline - Week 24

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100032, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2019, 16 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 16 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2017
First posted
Aug 21, 2017
StartActual
Nov 24, 2017
Primary completionActual
Apr 16, 2019
CompletionActual
Oct 12, 2019
Last update
Sep 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03254966
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Nov 24, 2017
Primary completion
Apr 16, 2019
Completion
Oct 12, 2019
Last update
Sep 30, 2021

Study contacts

Xiaofeng Zeng
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion